Ipsen Pharma

Oncology

Clinical research in solid tumours spans multiple advanced and metastatic cancer settings, with interest in disease control, tumour response, and treatment options after prior systemic therapy.

  • Renal cell carcinoma
  • Colorectal cancer
  • Pancreatic adenocarcinoma
  • Head and neck squamous cell carcinoma
  • Melanoma

Research activity also includes locally advanced and metastatic solid tumour populations, with attention to immunotherapy-exposed disease and treatment-resistant cancer.

Hepatology and Cholestatic Liver Disease

Studies cover cholestatic liver disorders and related paediatric and adult conditions, with focus on symptom relief, liver function, and long-term disease management.

  • Primary biliary cholangitis
  • Primary sclerosing cholangitis
  • Alagille syndrome
  • Biliary atresia

Therapeutic interest extends to persistent pruritus and preservation of native liver survival in rare hepatobiliary disease.

Neurology and Movement Disorders

Clinical work in neurology includes treatment of upper limb spasticity across different causes, including post-stroke presentations, with emphasis on motor function and symptom reduction.

  • Upper limb spasticity
  • Post-stroke spasticity
  • Spasticity of any aetiology

Research in this area reflects interest in managing functional impairment associated with neuromuscular tone abnormalities.

Targeted and Immuno-Oncology Therapeutics

Development programmes include investigational agents for advanced solid tumours, with attention to anti-tumour activity, pharmacodynamics, and treatment tolerability in adults with refractory disease.

  • Immune checkpoint inhibitor-exposed tumours
  • Pharmacokinetics and immunogenicity
  • Antitumour activity
  • Dose optimisation in selected tumours

These programmes include novel oncology compounds evaluated across several tumour types and treatment contexts.

Rare Disease and Gastrointestinal Supportive Care

Additional research interests include rare paediatric and hepatobiliary conditions, alongside disease-related symptom management and long-term safety in chronic disorders.

  • Rare cholestatic disorders
  • Paediatric liver disease
  • Chronic pruritus
  • Long-term safety in rare disease

Clinical activity also touches on advanced pancreatic cancer and other gastrointestinal malignancies, linking oncology with supportive disease management.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A Study of IPN01203 for Adults With Advanced or Metastatic Solid Tumors After Immune Checkpoint Inhibitor Treatment

    Recruiting

    2 1 1
    France Spain
  • A Study of IPN60300 in Adults with Locally Advanced or Metastatic Solid Tumors to Assess Safety, Tolerability and Anti-Cancer Activity

    Recruiting

    2 1 1
    France Spain
  • Study on the Safety and Effects of IPN01195 in Adults with Advanced Solid Tumors

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain
  • Study on Long-term Effects and Safety of Odevixibat in Children with Biliary Atresia

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium France Germany Hungary Italy The Netherlands +2
  • Efficacy and Safety Evaluation of Odevixibat in Pediatric Biliary Atresia Post-Kasai Hepatoportoenterostomy: A Double-Blind, Randomized, Placebo-Controlled Trial

    Not recruiting

    3 1
    Investigated drugs:
    Belgium France Germany Hungary Italy The Netherlands +2
  • Comparing Abobotulinumtoxin A and Onabotulinumtoxin A for Adults with Upper Limb Spasticity

    Not recruiting

    3 1 1 1
    Investigated diseases:
    France